The Medicines and Healthcare products Regulatory Agency (MHRA) has published a Drug Safety Update (DSU) informing healthcare professionals that fezolinetant treatment is associated with a risk of drug induced liver disease.
Fezolinetant is used for the treatment of moderate to severe vasomotor symptoms, including hot flushes and night sweats, associated with the menopause. There have been cases of liver problems in people taking fezolinetant, which were generally reversible following discontinuation of treatment.
Liver function should now be monitored before and during treatment, in all patients taking fezolinetant. Fezolinetant should be avoided in patients with known liver disease or at a higher risk of liver disease.
For more information, please read the DSU advice for healthcare professionals which includes advice for healthcare professionals to provide to patients and carers.
Healthcare professionals, patients and caregivers are asked to report suspected reactions on a Yellow Card.